Literature DB >> 35905485

UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.

Dean Elterman1, Mélanie Aubé-Peterkin2, Howard Evans3, Hazem Elmansy4, Malek Meskawi5, Kevin C Zorn5, Naeem Bhojani5.   

Abstract

Entities:  

Year:  2022        PMID： 35905485      PMCID： PMC9343161          DOI： 10.5489/cuaj.7906

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   2.052


× No keyword cloud information.
  113 in total

1.  Prostate Artery Embolization in Patients with Prostate Volumes of 80 mL or More: A Single-Institution Retrospective Experience of 93 Patients.

Authors:  Shivank Bhatia; Vishal K Sinha; Sardis Harward; Christopher Gomez; Bruce R Kava; Dipen J Parekh
Journal:  J Vasc Interv Radiol       Date:  2018-09-11       Impact factor: 3.464

Review 2.  Alpha adrenoceptor antagonists in the year 2000: is there anything new?

Authors:  C R Chapple
Journal:  Curr Opin Urol       Date:  2001-01       Impact factor: 2.309

Review 3.  Pygeum africanum for benign prostatic hyperplasia.

Authors:  T Wilt; A Ishani; R Mac Donald; I Rutks; G Stark
Journal:  Cochrane Database Syst Rev       Date:  2002

4.  Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.

Authors:  Malcolm G Lucas; Timothy P Stephenson; Vinod Nargund
Journal:  BJU Int       Date:  2005-02       Impact factor: 5.588

5.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

6.  Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study.

Authors:  Claus G Roehrborn; Jack Barkin; Steven N Gange; Neal D Shore; Jonathan L Giddens; Damien M Bolton; Barrett E Cowan; Anthony L Cantwell; Kevin T McVary; Alexis E Te; Shahram S Gholami; William G Moseley; Peter T Chin; William T Dowling; Sheldon J Freedman; Peter F Incze; K Scott Coffield; Sean Herron; Prem Rashid; Daniel B Rukstalis
Journal:  Can J Urol       Date:  2017-06       Impact factor: 1.344

7.  Durability of 30-minute high-energy transurethral microwave therapy for treatment of benign prostatic hyperplasia: a study of 213 patients with and without urinary retention.

Authors:  Stavros Gravas; Pilar Laguna; Lambertus A L M Kiemeney; Jean J M C H de la Rosette
Journal:  Urology       Date:  2007-05       Impact factor: 2.649

Review 8.  Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression.

Authors:  Jonathan M Levitt; Kevin M Slawin
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

Review 9.  Long-term results of open transvesical prostatectomy from a contemporary series of patients.

Authors:  Ioannis Varkarakis; Zacharias Kyriakakis; Athanasios Delis; Vasilios Protogerou; Charalambos Deliveliotis
Journal:  Urology       Date:  2004-08       Impact factor: 2.649

10.  Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study.

Authors:  Siddangouda B Patil; Kshitiz Ranka; Vinay S Kundargi; Nilesh Guru
Journal:  Cent European J Urol       Date:  2017-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.